Literature DB >> 7915095

Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions.

C Pechoux1, Y Chardonnet, P Noël.   

Abstract

The c-erb-B2 protein expression was evaluated by immunohistochemistry in two series of breast lesions. In a retrospective study on a series of 140 breast lesions, among 34 benign lesions, 16 showed an intense or moderate membrane reaction of tumoral cells; of 15 atypical lesions, 6 exhibited a membrane reaction and 34/60 in situ lesions expressed intensely or moderately c-erb-B2 oncoprotein. A prospective investigation was made on a series of 41 lesions from 25 patients, which were selected for their clinico-pathological features. All the samples were positive but the staining intensity was heterogenous. However, it was similar in the various lesions from the same patient. A strong signal was observed in 12 lesions from 7/25 patients, moderate in those of 13 patients and weak in 6 lesions from 5 patients. Taken together, our findings show that a large number of human breast lesions expressed c-erb-B2 oncoprotein, whether benign, atypical or in situ carcinomas. The intensity of the reaction may depend on the patients rather than on the aggressivity of the lesion, except for the infiltrating carcinomas. This suggests that c-erb-B2 oncoprotein in overexpressed at early stages of breast cancer lesions. Although c-erb-B2 oncoprotein is probably not a good marker for prognosis, it may be an indication for a future progression towards or recurrence.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915095

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Authors:  S W Beenken; W E Grizzle; D R Crowe; M G Conner; H L Weiss; M T Sellers; H Krontiras; M M Urist; K I Bland
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

2.  FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.

Authors:  W R Xing; K W Gilchrist; C P Harris; W Samson; L F Meisner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

Review 4.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.